Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Karuna Therapeutics, Inc. (KRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates On track to submit New Drug Application for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a product launch in the second half of 2024, assuming approval Initiated the Phase 3 ADEPT-3 open label extension trial in the third quarter of 2023, and on track to commence the Phase 3 ADEPT-2 trial in the second half of 2023 Announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Officer $1.4 billion in cash expected to fund operations through 2026 Conference call and webcast to take place today at 8:00 a.m. ET"
02/23/2023 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates Topline data from Phase 3 EMERGENT-3 trial anticipated in the first quarter of 2023 On track to submit New Drug Application for KarXT in schizophrenia to the U.S. Food & Drug Administration in mid-2023 Announced exclusive global license agreement for investigational TRPC4/5 inhibitors, including lead clinical-stage candidate KAR-2618 , in the first quarter of 2023 $1.1 billion in cash is expected to fund operations through the end of 2025"
08/08/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively On track to initiate the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who inadequately respond to current standard of care in the fourth quarter of 2021 Company plans to initiate a Phase 3 program evaluating KarXT for the treatment of psychosis in elderly patients with Alzheimer’s disease in mid-2022 $498.9 million in cash expected to fund operations, including multiple milestones, for at least 12 months following the potential New Drug Application submission of KarXT in schizophrenia"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update"
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update"
03/24/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update"
08/08/2019 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Second Quarter 2019 Financial Results and Provides General Business Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy